Aberrant histone acetylation was physiopathologically associated with the development of acute myeloid leukemias (AMLs). Reversal of histone deacetylation by histone deacetylase inhibitor (HDACis) activates a cell death program that allows tumor regression in mouse models of AMLs. We have used several models of PML-RARA-driven acute promyelocytic leukemias (APLs) to analyze the in vivo effects of valproic acid, a well-characterized HDACis. Valproic acid (VPA)-induced rapid tumor regression and sharply prolonged survival. However, discontinuation of treatment was associated to an immediate relapse. In vivo, as well as ex vivo, VPA-induced terminal granulocytic differentiation. Yet, despite full differentiation, leukemia-initiating cell (LIC) activity was actually enhanced by VPA treatment. In contrast to all-trans retinoic acid (ATRA) or arsenic, VPA did not degrade PML-RARA. However, in combination with ATRA, VPA synergized for PML-RARA degradation and LIC eradication in vivo. Our studies indicate that VPA triggers differentiation, but spares LIC activity, further uncouple differentiation from APL clearance and stress the importance of PML-RARA degradation in APL cure.
INTRODUCTION
Histone hyperacetylation correlates with an open, decondensed chromatin structure and transcriptional activation, whereas hypoacetylation correlates with a condensed chromatin structure and transcriptional repression. 1 Accordingly, aberrant activity of histone deacetylases (HDACs) has been observed in many tumors and proposed to be a hallmark of cancer. HDAC inhibitors (HDACis) reverse these tumor-associated aberrant epigenetic states and many compounds are in clinical development. 2 Several studies have demonstrated that HDACis are potent antiproliferative agents with relatively little effect on normal tissues. Although numerous mechanisms have been proposed, in particular activation of death receptor pathways, 3, 4 the actual mechanism by which the antitumor activity of HDACis is mediated remains under intense investigation. 5 Hematological malignances, such as myeloid leukemias, seem to be particularly sensitive to compounds with HDAC inhibitory activity. Acute promyelocytic leukemia (APL) was the first model disease in which the involvement of HDACs was proposed.
6,7 APL represents 10 --15% of acute myeloid leukemias (AMLs) in adults, and it is caused by a variety of chromosomal translocations into the retinoic acid receptor-a (RARA) gene. 8 The two most common fusion proteins in APLs, PML --RARA and promyelocytic leukemia zinc-finger protein (PLZF) --RARA, recruit nuclear-corepressor containing HDAC and DNA methyltransferases on the retinoic acid target genes, resulting in their transcriptional silencing, and culminating in differentiation arrest and acquisition of self-renewal. 8 All-trans retinoic acid (ATRA), the active derivative of vitamin A and the physiological ligand of RARA, elicits complete remission of PML-RARA-driven APLs at pharmacological doses, and has been successfully used in treatment of APLs. 9 --11 Nevertheless, PLZF --RARA fusion is associated with a ATRAresistant variant of the disease. 12 It was recently proposed that the transcriptional activation of differentiation programme may not be the primary basis for clearing APLs. 10,13 --15 Indeed, only leukemia-initiating cells (LICs) clearance is responsible for the cure of mouse APLs. High concentrations of ATRA lead to LIC loss, thus APL eradication, most likely through PML-RARA catabolism. However, in patients, ATRA does not lead to complete remission without accompanying chemotherapy, 16, 17 and some patients may develop resistance. 18 Valproic acid (VPA) belongs to the class I HDACi, which has been widely used as an antiepileptic drug. VPA induces growth arrest, differentiation and apoptosis in many leukemic cell lines, as well as in fresh leukemic blasts. 1, 19, 20 Similar results have been reported in mouse models of PML-RARA-or AML/ETO-driven leukemias, where VPA treatment significantly increases survival of leukemic mice through activation of the death receptor pathway. 3, 21 These observations, together with the well-established safe profile of VPA, have allowed several clinical trials using VPA either as monotherapy or in combination with ATRA in APLs and AMLs. 22 --25 However, despite some initial responses, complete remissions have only exceptionally been observed and do not appear to be durable. Why the well-characterized induction of cell death does not secure better remissions remains unclear.
Here, we evaluated the therapeutic effect of VPA in mouse models of APLs. We observed that VPA induces granulocytic differentiation of leukemic cells in vivo, but did not clear LICs. Nevertheless, VPA exhibits a synergistic effect with ATRA to clear LICs. These findings further uncouple differentiation from APL eradication and have important clinical implications for future trials.
MATERIALS AND METHODS

Cell culture and viruses
Retroviruses were obtained by transient transfection of Plat-E cells with various pMSCV-based retroviral vectors containing the PML-RARA cDNA (pMSCV-PML-RARA), 26 the full-length human PLZF(B)-RARA cDNA (pMSCV-PLZF-RARA) 27 or the MLL --ENL cDNA (pMSCV-MLL-ENL). 28 An empty vector served as a control. Lineage-depleted mouse hematopoietic cells collected from 5-fluorouracil-treated mice were infected with these retroviruses. 29, 30 After spinoculation, transduced cells were cultured in a methylcellulose medium (StemCell Technologies, Grenoble, France) supplemented with 100 ng/ml stem cell factor and 10 ng/ml each of interleukin-3, interleukin-6 and granulocyte-macrophage colony-stimulating factor (AbCys, Paris, France), with G418 for selection. After 1 week, neomycin-resistant cells were harvested and plated (10 000 cells per well) in the presence or absence of the drugs.
Leukemic blast cells were obtained from the spleen of leukemic APL mice and cultured (10 000 cells per well) in the methylcellulose medium, already supplemented with recombinant cytokines (GF M3434, StemCell Technologies) in the presence or absence of the drugs. A volume of 1 mM VPA was used alone or in combination with 1 mM ATRA (Sigma, St Louis, MO, USA). Upon a week of treatment, colonies were counted and cells were harvested, washed and, when specified, plated in the methylcellulose medium for a further week without drugs. In parallel, the percentage of both CD11b-and Gr1-positive cells was analyzed by flow cytometry.
In vivo mouse studies PML-RARA APLs in the C57Bl/6 and FVB/N background were described previously, 31, 32 and are referred to here as mCG-PML-RARA and MRP8-PML-RARA mice, respectively.
Briefly, for APL development 10 7 APL cells were injected intravenously into non-irradiated congenic (C57Bl/6-Ly5.1) or syngenic (FVB/N) recipients and then treated when the blast cells were detected in the recipients' peripheral blood and reached 60 --70% in the bone marrow. We administered VPA (Sigma) intraperitoneally at the dose of 400 mg/kg twice a day. ATRA (Innovative Research of America, Sarasota, FL, USA) was administered as subcutaneous 10 mg pellets releasing a daily constant quantity of drug. In the case of the mCG-PML-RARA model, the percentage of Ly5.2 þ cells in peripheral blood of Ly5.1 þ recipient mice was analyzed by flow cytometry. After treatment, mice were euthanized and cells were extracted from both the spleen and the bone marrow. For the evaluation of drug effects on differentiation, cells were cytospun and stained with May-Grunwald Giemsa as described previously. 24 The percentage of specific cell subsets in the bone marrow and spleen was analyzed by flow cytometry.
In the third model, 33 lineage-depleted cells from 129sv mice are purified, transduced with PML-RARA-expressing retroviral vector and injected in 129sv mice. Briefly, one million of leukemic cells (from 129sv mice) were injected intravenously into non-irradiated syngeneic recipients. Owing to the impossibility of using the Ly5.1/Ly5.2 congenic system to distinguish the donor from endogenous cells as for the previously described model, mice were treated when blast cells were detected in the recipients' peripheral blood (9 days after injection).
To evaluate drug effects on transplantation capacity of LICs, in the case of the MRP8-PML-RARA model, 3 Â 10 6 bone marrow blasts were injected into three secondary syngenic recipient mice per primary recipient. Two mice for each treatment modality and time point were used. For the mCG-PML-RARA model, Ly5.2 þ leukemic blasts from a subset of treated and untreated mice were sorted on FACSAria (BD Biosciences, San Jose, CA, USA) and injected into secondary congenic recipients in decreasing doses (from 2 Â 10 6 to 2 Â 10 4 cells). Mouse experiments were repeated two to five times, with highly similar or identical results, but experiments showed depict a single experiment.
Mouse care and experimental procedure were performed in accordance with established institutional guidance and approved protocols from the Comité Ré gional d'Ethique Expé rimentation Animale n14, and according to the Italian laws (D.L.vo 116/92 and following additions), which enforce the EU 86/609 directive.
Protein analyses
A total of 2.5 Â 10 5 bone marrow blast lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto the nitrocellulose membranes. Detection was carried out using rabbit polyclonal antibodies to RARA (RP115, kind gift of P Chambon, IGBMC, Strasbourg, France) and SuperSignal West Pico chemiluminiscent substrate (Pierce Biotechnology, Rockford, IL, USA). b-Actin was used as a loading control.
Flow cytometry analysis
For analysis of myeloid differentiation markers, hematopoietic-transduced cells and leukemic APL cells from ex vivo methylcellulose assays, and leukemic bone marrow cells from transplanted mice were blocked with rat immunoglobulin G and then stained with fluorochrome-conjugated monoclonal antibodies to CD11b, cKit and Gr1 (clone RB6-8-C5, eBioscience, San Diego, CA, USA).
For analysis of the congenic transplantation, after erythrocyte lysis with ACK buffer, peripheral blood samples were blocked with 1% rat serum and stained with fluorochrome-conjugated monoclonal antibodies directed against Ly5.2 (clone 104) or Ly5.1 (clone A20, both from eBioscience), to distinguish donor and recipient cells, respectively. Cells were washed twice and resuspended in 2% fetal bovine serum in Hank's balanced salt solution, supplemented with 0,5 mg/ml propidium iodide to exclude dead cells during analysis.
Statistics
Two-sided t-test was used to validate the significance of the observed differences. Kaplan --Meier rank test was used to compare the survival rate between treated and non-treated mice. In both test differences were considered statistically significant when Po0.05.
RESULTS
VPA induces differentiation, but enhances clonogenic activity methylcellulose cultures
To determine the effect of VPA on proliferation and differentiation of APL-like cells ex vivo, lineage-depleted murine hematopoietic progenitors cells were infected with PML-RARA or PLZF-RARAexpressing viruses, and grown in the methylcellulose medium. VPA treatment did not result in quantitative differences in the number of PML-RARA colony-forming cells (Figure 1a) , whereas it significantly enhanced growth of PLZF-RARA-expressing cells compared with untreated cultures (Po0.001; Figure 1b) . Nevertheless, VPA induced a differentiated phenotype, as showed by increased levels of myeloid Gr1 and CD11b markers (Figures 1a  and b) . These VPA effects were also found in MLL-ENL-transformed haematopoietic progenitors (Supplementary Figure S1A) , thus they do not appear to be associated with a specific cytogenetic subtype of AML. As shown previously, 26, 29 ATRA both drastically reduced the number of colonies and led to terminal granulocytic maturation of either PML-RARA-and PLZF-RARA-expressing cells (Figures 1a and b) . Unexpectedly, VPA partially rescued this anticlonogenic effect of retinoic acid, although the combination of the two drugs synergized for granulocytic differentiation (Figures 1a and b) . Thus, in this model system, VPA triggers terminal differentiation, but paradoxically enhances clonogenic activity, notably in the presence of ATRA.
Turning to primary APL blasts from PML-RARA-transduced 129SV grown in methylcellulose culture ex vivo, ATRA also resulted in a striking decrease of colony-forming units (Figure 1c) , and induction of differentiation (Supplementary Figure 1B , right panels). Though reduced in number, VPA-treated colonies became thick and larger than untreated ones (Supplementary Figure 1B , left panels). Furthermore, they gave rise to a higher number of secondary colonies, when they were cultured for an additional week in the absence (Figure 1d ) or in the presence of VPA (data not shown). VPA slightly counteracted ATRA effects in reducing clonogenicity (Figure 1d) , and again exhibited synergism in inducing myeloid maturation (Supplementary Figure 1B) .
These ex vivo experiments demonstrate in two different cellular systems that VPA triggers induction of terminal myeloid differentiation and a paradoxical enhancement of clonogenic capacity.
VPA induces tumor regression and APLs differentiation in vivo
To further investigate the relevance of these VPA effects in vivo, we turned to three APL transplantation models, derived from mCG-PML-RARA and MRP8-PML-RARA transgenic mice or retroviraly transduced primary progenitors (see Materials and Methods). Transplantation of leukemic bone marrow or spleen cells to wildtype syngeneic or congenic recipients allowed the generation of a large cohort of mice with similar time of onset of leukemia, 34 providing a highly reproducible APL model suitable for preclinical studies of therapeutic interventions against APL LICs in the setting of the in vivo host microenvironment.
We first conducted survival studies on mCG-PML-RARA-and retrovirus-driven APL, after 27 days exposure to VPA. Control mice all died during the treatment period, whereas treated mice showed a marked extension of survival (P ¼ 0.0001, Figure 2a ; Supplementary Figure 2A) . Moreover, treatment resulted in the decreased percentage of both circulating donor leukemic blasts (Ly5.2 þ cells in mCG-PML-RARA mice, Figure 2b ; Supplementary Figure 2B ) and immature cells (Supplementary Figure 2C) . However, all mice very rapidly died of leukemia upon treatment discontinuation. During VPA treatment, we observed significant Figure 2D) , together with clearcut differentiation (data not shown), consistent with our previous observations of VPA-triggered cell death. 3 VPA also induced massive apoptosis when these cells were grown ex vivo (data not shown). Similarly, in MRP8-PML-RARA mice, a clearcut loss in the spleen weight (an indirect reflection of the tumor mass) was observed as soon as 3 days (Po0.02; Figure 2c ). This was accompanied by induction of myeloid differentiation in the bone marrow (Figure 2d ) and spleen (data not shown).
In summary, VPA significantly extends survival of leukemic APL mice in three different APL models. This gain of survival can be ascribed to apoptosis 4, 35, 36 and induction of terminal granulocytic differentiation, both resulting in the subsequent elimination of leukemic cells. However, as soon as the treatment is suspended, the disease immediately relapses and all mice rapidly die of leukemia.
VPA differentiates APLs without LIC loss We first transplanted the bone marrow from 7-days VPA-treated or -untreated MRP8-PML-RARA mice into secondary recipients. Cells from VPA-treated animals were fully differentiated, similar to those treated with ATRA ( Figure 3a, upper panel) . Flow cytometry analyses confirmed that VPA-induced differentiation did not allow the restoration of normal hematopoiesis (Figure 3a, lower panel) . Unexpectedly, engraftment of treated or untreated cells resulted in very similar kinetics of leukemia development, despite full granulocytic differentiation of VPA-treated cells (Figures 3a and b) . Critically, when we assessed the expression of PML-RARA in the bone marrow, we observed similar protein levels to untreated mice, whereas in ATRA-treated mice PML-RARA was undetectable ( Figure 3c ).
As morphological differentiation does not change the LIC activity of VPA-treated APLs, we looked for the presence of APL cells with leukemia-initiating potential. 37, 38 Immunophenotypic analysis of both the bone marrow and spleen cells revealed the expansion of a leukemic (Ly5.2 þ ) myeloid (Gr1 þ /FcgRII-III þ ) stem-like (c-kit þ /CD34 þ ) subset after 27 days of treatment with VPA, when compared with untreated APLs (Figure 4a ). To directly demonstrate that VPA expands LIC subpopulation in vivo, we performed limiting dilution transplant assays of leukemic APL blasts after two (Figure 4b ) and 27 days (data not shown) of treatment. This demonstrated that LIC frequency in VPA-treated mice was indeed higher than in untreated recipients (*Po0.05, Figure 4b , data not shown), thus indicating that VPA enhances the proliferative and/or self-renewal potential of APL LICs. These observations explain the rapid relapse of APL mice upon treatment discontinuation.
Thus, differentiation can occur in the absence of any PML-RARA loss and does not affect LIC activity, reminiscent of ATRA-treated PLZF-RARA-driven APLs. 13, 15, 39 These observations further strengthen the proposed link between LIC activity and PML-RARA loss. 10, 14, 39 VPA may synergize with ATRA for LIC clearance in vivo We then analyzed the effect of the combination of VPA and ATRA in vivo. Interestingly, when primary leukemias were pre-treated with VPA for 1 day, PML-RARA protein levels were reduced in ATRA plus VPA-treated mice compared with ATRA-treated ones (Figure 5a ), though differentiation was essentially unaltered at 2 days of exposure to drugs (Figure 5b) . Unexpectedly, VPA also synergizes with ATRA in reducing LIC frequency in secondary recipient mice in both mouse models (Figure 5c for MRP8-PML-RARA; Figure 5d for mCG-PML-RARA). Furthermore, combined treatment resulted in significantly enhanced survival of primary leukemic recipients (Po0.01 vs ATRA, Po0.001 vs VPA; Figure 5e ). These data demonstrate that VPA exhibits synergism with retinoic acid for efficient PML-RARA degradation and also APL LIC targeting (see Discussion).
We then turned to a PLZF/RARA mouse model and examined the effect of VPA and ATRA. A 4 days ATRA treatment induced terminal differentiation, but a modest loss in disease burden and clonogenic activity 13 (Supplementary Figure S3A) . VPA induced some differentiation and loss in APL burden, but did not affect clonogenic activity. Unexpectedly, the ATRA/VPA synergy for elimination of clonogenic cells observed in the PML/RARA model was not found with the PLZF/RARA model.
DISCUSSION
Investigating in vivo effect of VPA in different models of PML/ RARA-driven APLs, we found that VPA-induced terminal differentiation, but actually enhances clonogenic activity. Our results strengthen the uncoupling between differentiation and APL clearance, as well as the links between PML-RARA protein expression and LIC activity.
We focused on VPA, whose anti-leukemic activity has been previously demonstrated for tumor regression and survival in different models of APLs as well as other AMLs. 3, 19 In vivo, VPA treatment-induced rapid tumor regression in three different mouse models of APLs, significantly extending survival of APL mice. APL regression reflects activation of apoptotic pathways and induction of granulocytic maturation of leukemic promyelocytes. However, this improvement never yielded APL eradication as all mice rapidly died of leukemia immediately after withdrawal of the drug. This implies that VPA treatment per se is insufficient to eradicate leukemic stem cells. Indeed, we found that VPA actually increased the self-renewal of clonogenic progenitors in both the ex vivo or in vivo settings. In particular, VPA-induced expansion of a cell subpopulation expressing myeloid and stem markers (Gr1, FcgRII --III, c-kit and CD34), which is highly enriched for leukemiainitiating activity. 37 VPA also enhances the clonogenic activity of normal human hematopoietic precursors. 40, 41 Similarly, VPA may enhance, in vitro, clonogenic capacity of CD34 þ AML progenitor cells. 42, 43 Our findings explain the poor outcome of AML patients and even several cases of rapid disease progression in clinical studies using VPA. 23, 40 Our observations again uncouple differentiation from APL eradication and have important new implications for the underlying mechanisms. 10, 14 First, they support the model that granulocytic differentiation can be achieved through transcriptional derepression of PML-RARA-HDAC-silenced genes. Indeed, differentiation can be achieved without any PML-RARA loss. Second, our findings further link, in PML-RARA-driven APLs, LIC and absolute level of PML-RARA expression. Indeed, VPA allows fully differentiated APL cells expressing abundant PML-RARA protein to reinitiate APLs very efficiently. Conversely, in several models, VPA both enhances ATRA-induced PML-RARA degradation, LIC clearance and survival. Together with previous indications, 10, 14 these new findings converge on a model whereby transcriptional repression of myeloid differentiation program by PML-RARA-bound HDAC controls differentiation, while PML-RARA abundance controls LIC self-renewal. Further studies should elucidate why PLZF/RARA degradation does not suffice to clear clonogenic properties of these cells, 13 and why the VPA and ATRA did not synergize for their clearance in this model. Taken together, our results argue for the study of the effects of other HDACis and different epigenetic drugs (such as DNA and histone methylation modifying agents) on LIC clearance in other forms of AMLs, which we have started to explore systematically.
At present, we do not have an explanation for the apparent discrepancy between loss or protection of clonogenic activity by the VPA/ATRA combination in vivo and in vitro. Note in that respect, that in vivo studies provide more stringent models for PML-RARA function. 44 Indeed, while RARA suffices to immortalize progenitors, 29 even dominant-negative RARA never achieved APL development in vivo. 45, 46 The VPA ATRA synergy may either be mediated by synergistic PML-RARA degradation, possibly facilitated by PML acetylation 47 or be mediated by the unidentified mechanism(s) downstream of PML-RARA degradation responsible for LIC loss. This might be control of P53 activation, as the later is modulated by both PML-RARA and VPA-triggered acetylation. 48 --51 These preclinical studies suggest that VPA is unlikely to have major effects in AMLs, while in selected cases of therapy-resistant APLs, 52 the clearcut VPA/ATRA synergy may have some clinical utility. Combination of VPA with other drugs should also be explored. Of particular interest is the observation that combination of VPA with DNA demethylating agents has clear clinical benefits in other forms of AMLs and myelodysplastic syndromes. These could be ascribed to an effect of the combination therapy on LIC clearance. 53 
